EMA Authorised: Finlee (dabrafenib mesilate) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency has authorised Finlee (dabrafenib mesilate). The medicine is indicated for glioma and has orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Finlee (dabrafenib mesilate)

Snippet

Status: Authorised. Therapeutic area: Glioma. MAH: Novartis Europharm Limited. Decision date: 25/03/2026. Orphan medicine